| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6517847 | DOW PHARM | Topical gel delivery system |
Aug, 2020
(3 years ago) | |
| US10653656 | DOW PHARM | Topical pharmaceutical compositions for treating skin conditions |
Aug, 2038
(14 years from now) | |
| US11324710 | DOW PHARM | Topical pharmaceutical compositions for treating skin conditions |
Aug, 2038
(14 years from now) | |
Altreno is owned by Dow Pharm.
Altreno contains Tretinoin.
Altreno has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Altreno are:
- US6517847
Altreno was authorised for market use on 23 August, 2018.
Altreno is available in lotion;topical dosage forms.
Altreno can be used as topical treatment of acne vulgaris in patients 9 years of age and older.
The generics of Altreno are possible to be released after 22 August, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2021 |
Drugs and Companies using TRETINOIN ingredient
Market Authorisation Date: 23 August, 2018
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION;TOPICAL
More Information on Dosage
ALTRENO family patents
